Preclinical studies have demonstrated the mechanisms underlying the efficacy of JAK/STAT inhibition in CTCL by JAK inhibitors or agents with inhibitory effects on the JAK/STAT pathway. The gene discussed is SOAT1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.